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BACKGROUND. The noninferiority of a 6-week dosing schedule of lanreotide Auto-
gel (Lan ATG) at a dose of 120 mg compared with a 3-week dosing schedule of
lanreotide microparticles (Lan MP) at a dose of 60 mg was investigated in
patients with neuroendocrine tumors (NET).
METHODS. Patients who had sporadic, well differentiated NET with a low grade of
malignancy were recruited for this open-label, Phase III, multicenter trial. Patients
were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120
mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks).
Tumor markers, tumor size, and symptoms were assessed between baseline and
Week 18. Success was classified as a response that ranged from disappearance to
an increase <25% in tumor marker, tumor size, or symptom frequency.
RESULTS. Sixty patients were randomized, and 46 patients completed the study.
Both for tumor markers and for tumor size, Lan ATG was not inferior to Lan MP
(55% and 59% of patients responded on tumor markers, respectively; 68% and
66% of patients responded on tumor size, respectively). There were too few
symptomatic patients to compare carcinoid symptoms. Both treatments were tol-
erated well, and no safety concerns were identified.
CONCLUSIONS. Lan ATG at a dose of 120 mg every 6 weeks was as effective for
controlling NET as Lan MP at a dose of 60 mg every 3 weeks. Cancer 2006;107:
2474–81.  2006 American Cancer Society.
KEYWORDS: neuroendocrine tumors, lanreotide Autogel, microparticles, somato-
statin analogues.
N euroendocrine tumors (NET) are rare malignant neoplasms thatmay secrete various amines and hormones according to their
site of origin and histology. Symptoms of NET are caused mainly by
their secretory activity; for example, the most common form of NET,
carcinoid tumors, can cause the diarrhea and flushing of carcinoid
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syndrome.1 Medical therapy for patients with NET
has 2 main objectives: symptom control, which may
be obtained with a decrease in circulating hormones
and biogenic amines, and control of tumor growth.
Between 80% and 90% of NETs express somatostatin
receptors on their cell surfaces, allowing the somato-
statin analogues lanreotide and octreotide to bind
with high affinity to receptor subtypes 2 and 5.2,3
These analogues inhibit the signal-transmission path-
ways mediated by the somatostatin receptors, causing
a reduction in hormone and amine secretion that may
ameliorate tumor-related syndromes and stabilize tu-
mor growth.
Long-acting formulations of somatostatin analo-
gues substantially lower the number of injections
required to control NET. Lanreotide AutogelTM (Lan
ATG) (Ipsen, Paris, France) is injected every 4 weeks
at a dose of 60 mg, 90 mg, or 120 mg4; whereas lan-
reotide microparticles (Lan MP) (Ipsen) at a dose of
30 mg are injected every 7 to 14 days or every 14 to
28 days for the 60-mg dose (available only in some
markets).5–8 Therapeutic equivalence has been dem-
onstrated between Lan ATG and Lan MP in the con-
trol of hormone hypersecretion in patients with
acromegaly.9,10 Recent studies also have suggested
that Lan ATG at a dose of 120 mg is as effective for
controlling acromegaly when injected every 4 to 8
weeks as Lan MP every 7 to 14 days.11 However, both
equivalence between the lanreotide formulations and
the use of a dosing interval for Lan ATG extended
beyond 4 weeks have yet to be investigated in NET.
Therefore, the objective of the current study was to
assess the equivalence between Lan ATG at a dose of
120 mg every 6 weeks and Lan MP at a dose of
60 mg every 3 weeks in patients with NET.
MATERIALS AND METHODS
Patients
Eligible patients age 18 years or older who had a his-
topathologic diagnosis of sporadic, well differentiated
NET with low-grade of malignancy according to the
2000 World Health Organization international histo-
logic classification. Eligibility criteria also included
the absence of central nervous system metastasis
and an Eastern Cooperative Oncology Group (ECOG)
performance score of 0 to 2.12 Newly diagnosed
patients and previously treated patients could be en-
rolled; however, treatment with interferon, chemo-
therapy, or any other experimental drug was not
allowed within 30 days prior to inclusion. Patients
who had previously received lanreotide were ineligi-
ble. A wash-out period of 3 weeks or 6 weeks was
sufficient after use of immediate-release or slow-
release octreotide, respectively.
Previously treated patients were required to have
evidence of progressive disease, which was defined
as an increase 25% over the previous month’s
assessment of symptoms, and/or tumor markers
and/or lesion size. Patients with uncontrolled diabe-
tes mellitus or severe renal or liver impairment and
women who were pregnant, breastfeeding, or had the
potential to become pregnant during their participa-
tion in the study were ineligible. All patients gave
written, informed consent, and the study was ap-
proved by the institutional ethics committee of each
participating center. The study was conducted in full
conformance with the principles of the Declaration
of Helsinki13 and according to good clinical practice
guidelines.14
Study Design
The study was an open-label, Phase III trial that took
place in 17 centers across Italy. After a screening visit
and an appropriate wash-out period, patients were
randomized by an interactive voice-response system
to receive 1 of 2 treatments: Lan MP at a dose of
60 mg (intramuscular injections every 3 weeks) or Lan
ATG at a dose of 120 mg (deep subcutaneous injec-
tions every 6 weeks). Injections occurred at Weeks 0,
3, 6, 9, 12, and 15 with Lan MP and at Weeks 0, 6,
and 12 with Lan ATG. The duration of the study was
18 weeks, and final assessments occurred at Week
18. Patients were withdrawn from the study if they
required other anticancer treatments (e.g. chemo-
therapy, interferon, or radiotherapy) during the study,
if they received somatostatin analogues other than
the study drug, or if progression of the underlying
disease or a serious adverse event occurred.
Efficacy and Safety Assessments
Efficacy was measured according to the criteria pro-
posed by the Italian Trials in Medical Oncology
(ITMO) Group15 for evaluating syndrome control
(symptomatic response), marker control (biochemical
response), and tumor control (objective response; bidi-
mensional assessments). These criteria are reported in
Table 1.
Patients with tumor-related carcinoid syndrome
used a diary to record their symptoms. They ranked
the presence and severity of diarrhea, flushing, per-
spiration, or any other symptoms on a 4-point scale
during the 7 days before the Week 0, 6, 12, and 18
visits.
Chromogranin A (CgA) was the main tumor
marker assessed, and its levels were determined from
blood samples drawn at Weeks 0, 6, 12, and 18. The
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analysis of CgA was performed at a central labora-
tory. The method used was an enzyme-linked immu-
nosorbent assay from DAKO Automation (Glostrup,
Denmark) for the quantitative determination of CgA
in human plasma. The normal range was from 2 U/L
to 18 U/L.
Concentrations of 5-hydroxyindoleacetic acid (5-
HIAA) in the urine over 24 hours were assessed only
in symptomatic patients. If they were tested for 5-
HIAA, then patients were asked to amend their diet
for the 3 days before the test, so that it would not
interfere with the test. Thus, patients were asked not
to consume coffee, tea, alcohol, chocolate, vanilla,
bananas, tomatoes, peanuts, walnuts, almonds, liver,
or smoked fish. When appropriate, other markers
were determined: These included calcitonin, gastrin,
and glucagon.
Tumor size was measured by using either com-
puterized axial tomography (CT), magnetic reso-
nance imaging (MRI), X-ray, echotomography or, in
some patients, by using esophagogastroduodeno-
scopy or bone scan. This assessment was performed
at screening if such data had not been collected
within 30 days prior to screening, and evaluations
were repeated at Weeks 9 and 18. The same assess-
ment method was used at each time point: If differ-
ent assessment methods were used, then the patient
was not considered evaluable. Progression-free sur-
vival (PFS) and overall survival were determined both
for tumor markers and for tumor size.
Quality of life (QoL) was evaluated at Week 0, 6,
12, and 18 visits by means of the European Organiza-
tion for Research and Treatment in Cancer (EORTC)
QoL questionnaire (QLQ-C30). Patients were ques-
tioned using the functional scales (physical, role,
cognitive, emotional, and social function), the symp-
tom scale, the financial difficulties scale, and the
global health-related QoL scale. Tolerability was
assessed through the recording of adverse events
throughout the study. Blood samples drawn at Weeks
0, 6, and 18 were used for standard biochemical and
hematologic assessments. Gall bladder echotomogra-
phy studies were obtained at the same time as the
blood samples.
Analytic and Statistical Plans
The primary endpoint of the study was to demon-
strate the noninferiority of Lan ATG at a dose of 120
mg compared with Lan MP at a dose of 60 mg, as
assessed using the symptomatic, biochemical, or
objective responses, according to the ITMO criteria.
Data were processed by using the Dunnett and Gent
test, grouping responses as successes (complete
symptomatic response [CR], partial response [PR],
stable disease [SD]) or failures (progressive disease or
interruption of treatment for progressive disease or
death). Treatment with Lan ATG at a dose of 120 mg
was considered noninferior to Lan MP at a dose of
60 mg if the lower confidence limit (CL) of the differ-
ence between Lan ATG at a dose of 120 mg and Lan
MP at a dose of 60 mg, for the proportion of patients
whose treatment was successful, was included within
the noninferiority margin of 0.20.
For the sample size calculation, it was estimated
that the proportion of positive responses was 85%
in the Lan MP treatment arm, with an expected dif-
ference of 3% compared with the with Lan ATG treat-
ment arm. The a level was set to 5% (1-sided), and
the power was set to 80%. The primary analysis
population was the intention-to-treat (ITT) popula-
tion: This comprised all randomized patients who
received at least 1 dose of study drug and for whom
the baseline assessment and at least 1 postbaseline
assessment were available or patients who discontin-
ued the study because of death or inefficacy. The
safety population comprised all randomized patients
who received at least 1 dose of study drug. Patients
who discontinued treatment or who were lost to fol-
low-up were considered to have had a treatment fail-
ure. A ‘‘last observation carried forward’’ approach
was adopted for all other missing data. The Dunnett
and Gent test was used to determine proportional
noninferiority using 2  2 contingency tables. Differ-
ences between treatments were determined by com-
paring the 95% lower CL with the noninferiority
margin; comparisons between survival curves were
made using the log-rank test. Quantitative analyses
TABLE 1
Criteria for Evaluating Tumor Response According to the
Italian Trials in Medical Oncology Group*
Syndrome control (symptomatic response)
CR: Disappearance of all symptoms of syndrome
PR: Decrease by 50% in the number of symptoms or their severity
SD: Slight changes (worsening or improvement) of symptoms
PD: Increase by >25% of symptoms
Marker control (biochemical response)
CR: Marker levels within normal range
PR: Decrease by 50% of markers levels
SD: Slight changes (decrease by <50% or increase by <25%) of marker levels
PD: Increase by >25% of marker levels
Tumor control (objective response)
CR: Disappearance of all previous lesions
PR: Decrease by 50% of all previous lesions
SD: Decrease by <50% of all previous lesions or increase <25% of all previous
lesions
PD: Increase by >25% of all previous lesions or onset of new lesions
CR indicates complete response; PR, partial response; SD, stable disease; PD, progressive disease.
* See Bajetta et al., 1993.15
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of tumor marker levels and EORTC scores were
conducted by using repeated-measures analyses of
variance. Only clinical symptoms were described,
because a limited number of patients presented with
symptoms.
RESULTS
Patient Demographics and Disposition
Sixty patients were recruited into the current study
and were randomized equally between the Lan MP
and ATG treatment groups. Patient characteristics
at screening are listed in Table 2. All 60 patients
received 1 dose of study drug and comprised the
safety population. One patient in each group did not
undergo a postbaseline efficacy assessment: There-
fore, the ITT population comprised the remaining 58
patients. The study was completed by 46 patients. In
the Lan ATG group, 7 patients withdrew because of
disease progression, and 1 each withdrew because of
noncompliance and withdrawn consent. In the Lan
MP group, 2 patients withdrew because of disease
progression, 1 patient died, 1 patient was lost to fol-
low-up, and 1 patient discontinued because of pro-
gression in tumor marker levels (but not in tumor
size).
Efficacy Assessments
At screening, 19 patients had carcinoid syndrome
(Table 2), and symptomatic response data were avail-
able for 11 patients from the ITT population at the
last assessment. At baseline, diarrhea was reported
by 3 patients in the Lan MP group and by 9 patients
TABLE 2
Patient Characteristics at Baseline (Safety Population)
Characteristic
No. of patients (%)
Lan MP, 60 mg (N = 30) Lan ATG, 120 mg (N = 30) Total (N = 60)
Gender
Male 16 (53.3) 24 (80.0) 40 (66.7)
Female 14 (46.7) 6 (20.0) 20 (33.3)
Race
White 30 (100.0) 29 (96.7) 59 (98.3)
Black 0 (0.0) 1 (3.3) 1 (1.7)
Age (mean 6 SD), y 58.4 6 14.9 57.5 6 13.1 57.9 6 13.9
Tumor markers
Over the clinical cutoff value 28 (93.3) 25 (83.3) 53 (88.3)
Chromogranin A 28 (93.3) 25 (83.3) 53 (88.3)
Urinary 5-HIAA 1 (3.3) 7 (23.3) 8 (13.3)
Others 3 (10.0) 5 (16.7) 8 (13.3)
Site of primary tumor
Unknown 6 (20.0) 5 (16.7) 11 (18.3)
Known 24 (80.0) 25 (83.3) 49 (81.7)
Bowel 10 (33.3) 12 (40.0) 22 (36.7)
Pancreas 9 (30.0) 7 (23.3) 16 (26.7)
Lung 4 (13.3) 4 (13.3) 8 (13.3)
Other 1 (3.3) 2 (6.7) 3 (5.0)
Metastases present 27 (90.0) 30 (100.0) 57 (95.0)
Carcinoid syndrome
Present 7 (23.3) 12 (40.0) 19 (31.7)
Diarrhea 3 (10.0) 10 (33.3) 13 (21.7)
Flushing 5 (16.7) 8 (26.7) 13 (21.7)
Other 3 (10.0) 1 (3.3) 4 (6.7)
Previous treatment
None 7 (23.3) 6 (20.0) 13 (21.7)
Surgery 24 (80.0) 33 (110.0)* 57 (95.0)
Chemotherapy 6 (20.0) 7 (23.3) 13 (21.7)
Radiotherapy 1 (3.3) 3 (10.0) 4 (6.7)
Octreotide 14 (46.7) 18 (60.0) 32 (53.3)
Interferon 1 (3.3) 2 (6.7) 3 (5.0)
Lan indicates lanreotide; MP, microparticles; ATG, Autogel; SD, standard deviation; HIAA, hydroxyindoleacetic acid.
* Some patients underwent more than 1 surgery.
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in the Lan ATG group. The mean number of weekly
episodes decreased progressively from baseline (Fig. 1).
At baseline, flushing was experienced by 3 patients in
the Lan MP group and by 9 patients in the Lan ATG
group, with a mean number of weekly episodes of 0.80
and 0.90, respectively. After 18 weeks of treatment, the
mean number of weekly episodes was 1.39 in the Lan
MP group and 0.36 in the Lan ATG group. Three
patients who received Lan ATG achieved a CR over the
course of the study, 3 patients achieved a PR, and
3 patients had SD. One patient who received Lan MP
achieved a PR, and 1 patient had SD. Because of the
low number of symptomatic patients, no statistical
analysis was undertaken. Of the 11 patients who were
assessed, none had progression of symptoms over the
study period (Table 3).
At the screening visit, 53 patients had elevated
CgA levels, and 8 patients had increased levels of uri-
nary 5-HIAA (Table 2). From baseline to the end of
the study, median CgA levels decreased 20.2% with
Lan MP and 27.6% with Lan ATG. (The decrease in
CgA was evident from the first injection of Lan ATG
and was maintained up to Week 18.) Median levels
of urinary 5-HIAA decreased from 17.8 mg/24 hours
at baseline to 16.0 mg/24 hours at Week 18 of the
study in the 3 assessable patients in the Lan ATG
group (10.1%). A decrease from 111.0 mg/24 hours to
79.0 mg/24 hours (29%) was observed in the 1 patient
on Lan MP who had 5-HIAA assessed at study end. A
slightly greater proportion of patients had successful
biochemical response in the Lan ATG group (59%)
compared with the Lan MP group (55%), and the
noninferiority was significant at P  .032. The lower
CL of the difference in proportional success between
Lan ATG and Lan MP (0.1765) was within the margin
of noninferiority.
At screening, 90% of lesions in the ITT popula-
tion were measured with CT, 2% of lesions were
measured with MRI, and 8% of lesions were mea-
sured with techniques. The majority of patients in
both treatment groups had stable tumor dimensions
during the course of the study, and treatment was
categorized as a success in 68% of patients in the
Lan ATG group and in 66% of patients in the Lan MP
group (P ¼ .032 vs. ATG) (Table 3). The lower limit of
the CL between treatments was 0.1819.
There was no significant difference in PFS bet-
ween the 2 treatment groups measured either by tu-
mor marker or by tumor size (log-rank test; P > .05)
(Fig. 2) up to the final visit at Week 18. Furthermore,
there was no difference in the EORTC QLQ-C30 sum
of items score or in the individual subscale scores
between treatment groups at baseline or at study
end (Table 4).
Safety
Both Lan ATG and Lan MP were well tolerated. With
both formulations, the most frequent adverse events
were those that affected the gastrointestinal system
(Table 5). There were no serious or significant events
related to treatment. The patient who died during
participation in the study had an NET of pancreatic
origin with hepatic involvement, secondary localiza-
tions in the abdominal cavity, abdominal lymph
node involvement, and carcinoid syndrome. This
patient suffered from anxiety and depression and
had an episode of psychomotor agitation. He had
received a single, 60-mg injection of Lan MP and
died while he was hospitalized for a planned locore-
gional treatment of the liver. The investigator consid-
ered it unlikely that the event was related to the
somatostatin analogue treatment. The precise cir-
cumstances and immediate cause of death are
unknown.
An increase in the number of patients with hy-
perglycemia was noted over the treatment period.
At screening, 6 patients (10%) had blood fasting glu-
cose levels above the normal range, including 2 pa-
tients who were positive for noninsulin-dependent
diabetes mellitus. At the final visit of the study, 15 pa-
tients (25%) had glucose values above the normal
ranges, including 8 patients in the Lan ATG group
and 7 patients in the Lan MP group; but no patients
developed diabetes or clinically significant changes
in blood glucose levels. Low blood calcium levels
were noted at the final visit in 1 patient in the Lan
MP group and in 2 patients in the Lan ATG group.
No effect of Lan MP or Lan ATG was apparent on bil-
iary echography: In both treatment arms, 9 of 53 pa-
tients (17%) had abnormal scans at baseline, and 5
of 31 patients (16%) had abnormal scans at the end
of the study. Lithiasis was present in 3 of 53 patients
FIGURE 1. This chart illustrates that there was a reduction in the mean
weekly number of diarrhea episodes from baseline to Week 18 of treatment
(intention-to-treat population). For the Lanreotide Autogel group, there were
6 patients at 12 weeks and 7 patients at 18 weeks.
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(6%) at baseline and in 4 of 31 patients (13%) at the
end of the study.
DISCUSSION
The current results demonstrated that Lan ATG at a
dose of 120 mg every 6 weeks was as effective as Lan
MP at a dose of 60 mg injected every 3 weeks in
patients with sporadic, well differentiated NET with a
low grade of malignancy. These results were statisti-
cally significant both for the lowering of tumor
marker levels and for the reduction in tumor size.
Responses were categorized as successful if
patients had a CR, PR, or SD, according to the ITMO
Group criteria. Applying this system to CgA levels,
55% of patients had a successful response with Lan
MP at a dose of 60 mg compared with a 59%
successful response rate with Lan ATG at a dose of
120 mg. Likewise, with regard to tumor size, the rate
of success was 65% with Lan MP at a dose of 60 mg
and 68% with Lan ATG at a dose of120 mg. Symp-
toms were present in too few patients for a reliable
comparison between the 2 treatment groups. How-
ever, of the 11 patients who had symptoms at the
end of the study, none had developed disease pro-
gression.
The results from this study are in agreement with
previous studies of lanreotide or octreotide, the ma-
jority of which have shown efficacy in the control of
symptoms of carcinoid syndrome and a reduction in
the concentrations of tumor markers.4,5,16 Chromo-
granins are markers of secretory activity because they
are released from NET at the same time as amines
and peptide hormones. Therefore, the reduction in
circulating levels can parallel a decline in hormone
secretion and symptom severity or frequency, al-
though declining tumor markers do not necessarily
reflect a loss of tumor mass. Similar to the current
study, it was demonstrated previously that somatosta-
tin analogues stabilized tumor masses in patients with
progressive NET.5,6,17 Reductions in tumor size has
been reported but only as a minor response in a small
proportion of patients.18,19 Stabilization of tumor mass
itself is a relevant outcome for patients with NET.
In the current study, no differences were ob-
served between the 2 treatment groups in the QoL
assessment using the EORTC QLQ-C30 question-
naire, and no significant changes were observed be-
tween baseline and study end for any of the EORTC
QLQ-C30 scales. There are several possible explana-
TABLE 3
Treatment Success Over the Course of the Study Assessed by Using the Italian Trials in Medical Oncology Group Criteria
(Intention-to-Treat Population)*
Response
No. of patients (%)
Tumor markers (N = 56) Tumor size (N = 56) Symptoms (N = 11)
Lan MP, 60 mg Lan ATG, 120 mg Lan MP, 60 mg Lan ATG, 120 mg Lan MP, 60 mg Lan ATG, 120 mg
Complete 1 (3.6) 3 (11.1) 0 (0) 0 (0) 0 (0) 3 (33.3)
Partial 4 (14.3) 8 (29.6) 1 (3.6) 0 (0) 1 (50) 3 (33.3)
Stable 11 (39.3) 5 (18.5) 18 (64.3) 19 (67.9) 1 (50) 3 (33.3)
Progressive 12 (42.9) 11 (40.7) 9 (32.1) 9 (32.1) 0 (0) 0 (0)
Success 16 (55.2) 16 (59.3)y 19 (65.5) 19 (67.9)y — —
Failure{ 13 (44.8) 11 (40.7) 10 (34.4) 9 (32.1) — —
Lower CL 0.1765 0.1819 — —
Lan indicates lanreotide; MP, microparticles; ATG, Autogel; CL, confidence limit (calculated from differences between treatment success with Lan ATG and Lan MP).
* See Bajetta et al., 1993.15
y P < .032 Lan ATG versus Lan MP for ‘‘noninferiority.’’
{ Failures included 1 death that occurred 3 weeks after baseline.
FIGURE 2. This chart illustrates progression-free survival assessed by tu-
mor size (intention-to-treat population).
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tions for these similar scores. It is likely that, as a
generic oncology questionnaire, the QLQ-C30 is not
sufficiently specific for this patient population; thus,
it would be relatively insensitive to the changes in
patient QoL. This is acknowledged by the EORTC,
which currently is developing a tool that will be spe-
cific to NET. Therefore, it is possible that the ex-
pected benefit for the patient related to the
simplified mode of administration and fewer injec-
tions has not been picked up by the QLQ-C30 ques-
tionnaire. A further contributory factor may be that
>75% of patients had received previous treatment for
NET, and many may have been receiving a monthly
somatostatin analogue.
One limitation of the current study was that the
relative symptomatic efficacy of the 2 formulations
could not be assessed because of low patient num-
bers. The reason that few symptomatic patients were
recruited may be because many patients with carci-
noid syndrome are treated with lanreotide, and this
was an exclusion criterion for the study. It is note-
worthy that the low number of symptomatic patients
at baseline suggests that physicians want to prescribe
a drug with an antitumor effect for these patients
rather than a drug that is active against a cancer-
related syndrome.
Treatment with either Lan MP at a dose of 60 mg
or Lan ATG at a dose of 120 mg generally was toler-
ated well, and no safety issues were identified. The
most common adverse events were gastrointestinal
in nature, as reported previously. The proportion of
patients with cholelithiasis was not modified signifi-
cantly over the course of the study.
In conclusion, the current results indicated that
a 6-week dosing schedule with Lan ATG at a dose of
120 mg was as effective in controlling NET, as mea-
sured by tumor markers and tumor size, as a 3-week
dosing schedule with Lan MP at a dose of 60 mg.
The treatment was tolerated well, and no safety con-
cerns were identified. Therefore, an extended interval
of injection is an option for patients who respond
well to a somatostatin analogue; although, in clinical
practice, the dose would be titrated according to the
patient’s requirements.
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SD indicates standard deviation; Lan, lanreotide; MP, microparticles; ATG, Autogel; QoL, quality of life.
* Note that the maximal range of the scale was from 0 to 100.
TABLE 5
Adverse Events that Occurred in More than 1 Patient
(Safety Population)*
Adverse event
No. of patients
Lan MP (60 mg) Lan ATG (120 mg)
Abdominal pain 3 3
Constipation 0 2
Diarrhea 4 2
Pyrexia 2 3
Cholelithiasis 2 0
Dizziness 1 1
Bronchitis 0 2
Hypertension 0 2
Lan indicates lanreotide; MP, microparticles; ATG, Autogel.
* Multiple occurrences of the same adverse event in the same patient were counted only once.
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